4.3 Article

Genetic and Epigenetic Inactivation of Kruppel-like Factor 4 in Medulloblastoma

Journal

NEOPLASIA
Volume 12, Issue 1, Pages 20-27

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1593/neo.91122

Keywords

-

Categories

Funding

  1. Canadian Cancer Society
  2. Pediatric Brain Tumor Foundation of the United States
  3. Sontag Foundation
  4. CIHR
  5. Hospital for Sick Children
  6. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055089] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Although medulloblastoma is the most common pediatric malignant brain tumor, its molecular underpinnings are largely unknown. We have identified rare, recurrent homozygous deletions of Kruppel-like Factor 4 (KLF4) in medulloblastoma using high-resolution single nucleotide polymorphism arrays, digital karyotyping, and genomic real-time polymerase chain reaction (PCR). Furthermore, we show that there is loss of physiological KLF4 expression in more than 40% of primary medulloblastomas both at the RNA and protein levels. Medulloblastoma cell lines drastically increase the expression of KLF4 in response to the demethylating agent 5-azacytidine and demonstrate dense methylation of the promoter CpG island by bisulfite sequencing. Methylation-specific PCR targeting the KLF4 promoter demonstrates CpG methylation in approximately 16% of primary medulloblastomas. Reexpression of KLF4 in the D283 medulloblastoma cell line results in significant growth suppression both in vitro and in vivo. We conclude that KLF4 is inactivated by either genetic or epigenetic mechanisms in a large subset of medulloblastomas and that it likely functions as a tumor suppressor gene in the pathogenesis of medulloblastoma.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available